

1 **Antimicrobial Susceptibility Patterns in Adult Patients Hospitalized for**  
2 **Community-acquired Urinary Tract Infection in Tertiary Hospitals in Chile**

3  
4

5 **Luis Rojas 1,5 ¶, Inés Ceron 2&, Esteban Araos-Baeriswyl 1&, Paola Viviani 3&, Rodrigo Olivares 4¶,**  
6 **Andrés Valenzuela 1&, Andrés Aizman 1¶\***

7  
8  
9

1 Department of Internal Medicine. Pontificia Universidad Católica de Chile, Santiago, Chile.

10 2 Adult Infectious Diseases Department. Pontificia Universidad Católica de Chile, Santiago, Chile.

11

12 3 Public Health Department, Pontificia Universidad Católica de Chile, Santiago, Chile.

13

14 4 School of Medicine. Pontificia Universidad Católica de Chile, Santiago, Chile.

15

16 5 Pharmacology and Toxicology Program. Pontificia Universidad Católica de Chile, Santiago, Chile.

17

18

19 **\* Corresponding author**

20 E-mail: [andresaizman@gmail.com](mailto:andresaizman@gmail.com) (AA)

21

22 The authors contributed equally to this work.

## 23 **ABSTRACT**

24 Background: The constant increase of factors associated with the presence of resistant strains makes  
25 empirical antibiotic selection a challenge in patients hospitalized for community-acquired urinary tract  
26 infection. We characterized the type of bacteria and their antimicrobial susceptibility pattern in cultures  
27 obtained from adult patients that needed hospitalization for this disease in two tertiary hospitals in Chile.

28 Methods: We conducted a cross-sectional study in adults hospitalized for community-acquired urinary  
29 tract infection between 2017 and 2022. A total of 830 patients were included. All patients with positive  
30 cultures were included in the analysis.

31 Results: *Escherichia coli* was the most frequent infectious agent (68.1%), followed by *Klebsiella* spp.  
32 (17.7%) and *Enterococcus faecalis* (6.7%). Among *Enterobacteriaceae* strains, 35.2%, 19.7% and 27.2%  
33 were resistant to first, second and third-generation cephalosporin, respectively. 36.9% were resistant to  
34 ciprofloxacin and 1.8% to amikacin. Gram-positive bacteria were resistant to oxacillin and ampicillin in  
35 25% and 18%, respectively.

36 Conclusion: We detected a high prevalence of community-acquired urinary tract infections caused by  
37 bacteria resistant to commonly used antibiotics in adult patients that need to be hospitalized. In view of  
38 this, we believe that current medical guidelines should be reviewed and updated.

39 Keywords: urinary tract infection, adult inpatient, antimicrobial susceptibility test.

## 40 INTRODUCTION

41 Community-acquired urinary tract infection (CA-UTI) is one of the most frequent bacterial infections in  
42 the community and hospitalized patients (1,2). Most are caused by gram-negative enterobacteria, with  
43 *Escherichia coli* being the bacterium detected in more than 50% of cases (3). Their initial treatment is  
44 based on the empirical use of antibiotics for at least 48 hrs, until antimicrobial susceptibility studies are  
45 obtained (4). This initial empirical antibiotic selection is very important, because if it is inadequate,  
46 increases morbidity, costs, and length of stay in the hospital (5,6).

47 Local reports of antimicrobial susceptibility patterns in patients with community or hospital-acquired  
48 urinary tract infections provide important support for the selection of antibiotic treatment before  
49 receiving culture results (4). However, this information should be constantly updated due to the significant  
50 and constant increase in risk factors associated with the presence of resistant strains (7–11). The  
51 information should also specify whether samples correspond to ambulatory patients or those who  
52 required hospitalization for CA-UTI, the latter being a group at greater risk of suffering consequences due  
53 to an inadequate initial selection of antibiotics (12–15).

54 In view of the above, in addition to the scarce information published on the subject in Chile and Latin  
55 America, the aim of this study is to characterize the type of bacteria and their antimicrobial susceptibility  
56 pattern in cultures obtained from patients hospitalized for CA-UTI, with a view to determining the  
57 prevalence of bacteria resistant to first-line antibiotics.

## 58 MATERIALS AND METHODS

59 This was a cross-sectional study that incorporated prospective sampling in two hospitals/health centers  
60 within the Metropolitan Region of Chile: UC Hospital Clinic (HCUC) and Dr. Sotero del Rio Hospital (HSR),  
61 belonging to private and public health system, respectively. All patients over 18 years of age hospitalized  
62 for CA-UTI were recruited, in consecutive order. Patients included those who presented a UTI at the time  
63 of hospital admission, and those who developed UTI within the first 48 hours of hospitalization.

64 Patients not included in the sample were those with recent hospital stays (7 days prior), polymicrobial  
65 cultures, cultures from urinary catheter users without previous catheter change, fungal cultures, cultures  
66 from urine collection bags, cultures from patients with ileal reservoir, and positive cultures without  
67 antimicrobial susceptibility study.

68 The diagnosis of CA-UTI was based on the presence of suggestive symptoms (dysuria, pollakiuria, urinary  
69 incontinence, lumbar or flank pain, fever, chills and/or acute changes in mental status) associated to urine  
70 sediment with leukocyturia (> 10 leukocytes per field). Growth of a uropathogen in a urine culture was  
71 greater than or equal to 10<sup>5</sup> colony forming units (cfu)/mL from spontaneous urination samples, or  
72 greater than or equal to 10<sup>3</sup> cfu/mL if collected through bladder catheterization, urinary catheter  
73 puncture and/or bladder puncture (16,17). Urine samples were obtained by spontaneous urination of  
74 second stream urine, bladder catheterization, urinary catheter puncture and/or bladder puncture.  
75 Seeding was performed on chromogenic agar (CHROMID® CPS® Elite / Columbia CNA + 5% sheep blood  
76 Agar, bioMerieux) with 1 µL calibrated loop for second stream urine, 10 µL calibrated loop for  
77 catheterizations and urinary catheter puncture, and 100 µL for bladder puncture. Incubation was  
78 performed at 35°C for 16 hours in an aerobic environment. After incubation, colony counting and bacterial  
79 identification was performed by mass spectrometry (Matrix-Assisted Laser Desorption/Ionization Time-  
80 Of-Flight MALDI-TOF) in the Microflex® spectrometer, using the Biotyper® system (Bruker) and following  
81 the manufacturer's instructions. Antimicrobial susceptibility of *Escherichia coli* was performed on the  
82 automated VITEK 2 XL system® (bioMerieux) with the N-250 card (bioMerieux). The rest of the bacteria  
83 was analyzed by agar dilution, using the Cathra® multiplier (MCT Medical Inc. St. Paul, Minn.). The  
84 antibiotics included are as follows: nitrofurantoin, amikacin, gentamicin, cephalosporins, trimethoprim-  
85 sulfamethoxazole, ciprofloxacin, oxacillin and ampicillin (first-line antibiotics), piperacillin-tazobactam,  
86 carbapenems, cefoperazone-sulbactam, vancomycin, teicoplanin and linezolid (second-line antibiotics).  
87 The interpretation of the minimum inhibitory concentration (MIC) was performed for each antimicrobial  
88 and bacteria type, according to *Clinical and Laboratory Standards Institute (CLSI)* (18).

89 Data were obtained from clinical and laboratory service records, and were entered anonymously in a  
90 database implemented through the RedCap system.

## 91 **STATISTICS**

92 Categorical variables were expressed as frequencies and percentages, and numeric variables as medians  
93 and range, with a 95% confidence interval (CI 95%). The association between categorical variables was  
94 established using Fisher's exact test or Chi-square test as appropriate. An *a priori* alpha value of 5% was  
95 defined to establish statistically significant differences. The analyses were performed using the STATA v.  
96 14 software.

97 This study was approved by the Health Sciences Scientific Ethics Committee of the School of Medicine of  
98 the Pontifical Catholic University and the South-East Metropolitan Health Service (ID 2003005003).

## 99 RESULTS

100 A total of 830 patients were recruited between October 2017 and September 2021, of which 88.7% were  
101 recruited at the university's hospital clinic (HCUC) (n = 736). The mean age was 66.5 (range: 18 to 102  
102 years), 64.1% were female. All CA-UTI were diagnosed with urine cultures, 16.3% of all cases had  
103 concomitant positive blood cultures.

104 The most frequent comorbidities within the sample were diabetes mellitus (33.9%) and chronic renal  
105 insufficiency (21.4%). Of all patients, 43.3% presented at least one previous hospitalization during the last  
106 year. An indwelling urinary catheter had been used by 13.3% of patients at least 90 days prior to admission  
107 (mean days of use = 51.3, range = 1 to 365 days), of which 35.5% were using it at the time of admission.  
108 Some 28.3% presented anatomical or functional alterations of the urinary tract, and 14.1% had undergone  
109 instrumentalization of the urinary tract during the last year. About 24.5% had previous cultures for  
110 resistant bacteria in the last year, and 45.7% had used antibiotics in the last 90 days prior to admission.  
111 Regarding the severity of the clinical scenario, most of the patients (60.5%) were admitted to low  
112 complexity hospital units. The average length of stay was 10.5 days, the median was 7 days, and 5.1% died  
113 during their stay (**Table 1**).

114 **Table 1.** Clinical and demographic characteristics of the patients participating in the study.

### 115 Cultures

116 Enterobacteriaceae were the most frequent infectious agents identified. *Escherichia coli* was found in  
117 68.1% of cultures, *Klebsiella spp.* in 17.7%, *Proteus spp.* 4.6% and *Pseudomonas aeruginosa* 2.5%. Gram-  
118 positive pathogens were detected in 88 patients, including *Enterococcus faecalis* (6.7%), *Enterococcus*  
119 *faecium* (1.9%) and *Staphylococcus spp.* (1.9%). The distribution was similar between both  
120 hospitals/healthcare centers included in the study, except for *Klebsiella spp.*, which was more frequent in  
121 the Dr. Sotero del Rio Hospital (HSR) (**table 2**).

122 **Table 2.** Type of bacteria isolated in urine cultures, showing differences according to care center.

123 A lower prevalence of *Escherichia coli* was observed in male population compared to female population  
124 (51.7% vs 77.3%), with the opposite occurring for *Klebsiella spp* (24.2% vs 14.1%), *Enterococcus faecalis*  
125 (10.1% vs 4.9%), *Proteus spp* (7% vs 3.2%) and *Pseudomonas aeruginosa* (4.7% vs 1.3%). In turn, those  
126 older than 65 had a higher incidence of *Enterococcus faecalis* (8.2% vs 4.5%) and *Pseudomonas aeruginosa*  
127 (3.6% vs 0.9%) (**Table 3**).

128 **Table 3.** Type of bacteria isolated in urine cultures, showing differences by sex and age group in both  
129 recruiting centers

### 130 Antimicrobial Resistance

#### 131 *Escherichia coli*

132 Resistance rates for 1st generation cephalosporins, trimethoprim-sulfamethoxazole and ciprofloxacin  
133 exceeded 30%, and for 2nd and 3rd generation cephalosporins resistance rates were 15% and 20.5%,  
134 respectively. Resistance to nitrofurantoin was observed in only 3.9% of cases, being even lower for  
135 piperacillin-tazobactam and carbapenems (less than 1%). The same was observed for amikacin, but not  
136 for gentamicin (0.2% and 11.3%, respectively). (**Table 4**).

137 **Table 4.** Antibiotic resistance pattern for total bacteria found in urine cultures of patients with  
138 community-acquired urinary tract infection admitted to HCUC or HSR. N/A: not applicable

139 ***Klebsiella spp.***

140 Except for amikacin (6.8%), all 1st line antibiotics presented resistances above 30%. The highest rates were  
141 observed for 1st and 3rd generation cephalosporins, both with a 53.1% resistance, then for ciprofloxacin  
142 and trimethoprim-sulfamethoxazole (both 44.2%), and lastly for nitrofurantoin and gentamicin (both  
143 32.7%).

144 With respect to 2nd line antibiotics, less resistance was detected, 17.7% was found for ertapenem and  
145 piperacillin-tazobactam, 3.4% for imipenem, and 4.1% for meropenem. Of the latter (11 strains), three  
146 included carbapenemases (KPC), and two consisted of New Delhi metallo-beta-lactamase (**NDM**)  
147 carbapenemases. (**Table 4**).

148 ***Proteus spp.***

149 *Proteus spp.* presented resistance rates between 13% and 21% for 1st and 2nd generation cephalosporins,  
150 ciprofloxacin and trimethoprim-sulfamethoxazole. Similar resistance values were observed for 3rd  
151 generation cephalosporins (18.4%). In contrast to previous cases, a high resistance to nitrofurantoin was  
152 identified (86.8%), the highest observed in all the cultures recorded. Regarding aminoglycosides, 6.8% and  
153 32.7% resistance was observed for amikacin and gentamicin, respectively. No strains resistant to  
154 carbapenems were detected, and only 2.6% were resistant to piperacillin-tazobactam (**Table 4**).

155 ***Enterobacter Cloacae (complex)***

156 Of the 9 strains detected, 33% were resistant to ciprofloxacin, 44% to trimethoprim-sulfamethoxazole,  
157 nitrofurantoin and 3rd generation cephalosporins. They had higher resistance rates for aminoglycosides  
158 (22.2% for amikacin and gentamicin), piperacillin-tazobactam (33.3%) and ertapenem (33.3%). One strain  
159 showed resistance to imipenem, which was through the production of VIM carbapenemases (**Table 4**).

160 ***Pseudomona aeruginosa***

161 Of all the strains, 28.6% and 33.3% were resistant to ciprofloxacin and ceftazidime, respectively. Together  
162 with *Escherichia coli* strains, they presented the lowest resistance rates for piperacillin-tazobactam and  
163 amikacin (4.8% and 0%, respectively). In turn, the resistance observed for carbapenems was the highest  
164 (33.3% for imipenem and 14.3% for meropenem). None of them were carbapenemases producers (**Table**  
165 **4**).

166 ***Enterococcus faecalis and Enterococcus faecium***

167 Within the *Enterococcus faecalis* strains, 37.5% were resistant to ciprofloxacin and all were sensitive to  
168 ampicillin. Of the *Enterococcus faecium* strains, 81.3% were resistant to ampicillin and ciprofloxacin, and  
169 56.3% to vancomycin. They were all sensitive to linezolid (**Table 4**).

170 ***Staphylococcus spp.***

171 Within this group, composed of *Staphylococcus aureus* (9), *Staphylococcus* epidermidis (3),  
172 *Staphylococcus* haemolyticus (2) and *Staphylococcus* lugdunensis (2), 25% were resistant to oxacillin and  
173 all cases were sensitive to vancomycin (Table 4).

#### 174 Comparison of urine cultures according to origin and demographic variables

175 When comparing the prevalence of microorganisms from both healthcare centers, there were only  
176 differences for *Klebsiella spp.* (HCUC 16.6% and HSR 26.6%) (Table 2). Regarding antimicrobial  
177 susceptibility patterns for the two most frequent types of bacteria (i.e., *Escherichia coli* and *Klebsiella*  
178 *spp.*), greater resistance was observed for almost all antibiotics in the strains from the HSR, especially for  
179 1st generation cephalosporins, piperacillin-tazobactam, nitrofurantoin and ertapenem. (Table 5).

180 **Table 5.** Antimicrobial resistance profile for *E. coli* and *Klebsiella spp.* in each hospital center, antibiograms  
181 reported from urine cultures.

182 *Klebsiella*, *Proteus spp.*, *Pseudomona aeruginosa* and *Enterococcus faecalis* were more prevalent in men  
183 and *Escherichia coli* in women. Only enterobacteria behaved differently with respect to antibiotic  
184 resistance patterns, being higher in the male population.

185 In patients older than 65, a higher prevalence of *Enterococcus faecalis* was observed and there were no  
186 differences in antimicrobial susceptibility patterns. (Table 6).

187 **Table 6.** Overall antibiotic resistance patterns for bacteria found in urine cultures of patients with  
188 community-acquired urinary tract infection admitted to HCUC or HSR, showing differences by sex and  
189 age group. It should be noted that bacteria classified as \*other enterobacteria and \*\*other bacteria  
190 were not considered for the calculation of % resistance. The following were considered: *Escherichia coli*,  
191 *Klebsiella spp.*, *Enterococcus faecalis*, *Enterococcus faecium*, *Proteus spp.*, *Pseudomonas aeruginosa*,  
192 *Enterobacter cloacae*, *Staphylococcus spp.*

## 193 DISCUSSION

194 CA-UTI is a highly prevalent pathology and a frequent reason for hospital admission in the adult population  
195 (19–21). One of the factors that can determine morbidity and mortality is the correct initial empirical  
196 antibiotic choice, especially in patients who require hospitalization. To assist in the latter, it is necessary  
197 to identify antimicrobial susceptibility patterns. However, information regarding patients who require  
198 hospitalization has been poorly represented in available reports.

199 Our study recruited more than 800 patients requiring hospitalization with CA-UTI at two hospitals/health  
200 centers. The majority were women with ages close to 65. About 70% of the patients had more than one  
201 associated condition, as evidenced in previous reports, and presented bacteria resistant to first-line  
202 antibiotics. The most frequent causative agents were enterobacteria, *Escherichia coli* and *Klebsiella spp.*  
203 (68.1% and 17.7%, respectively). Similar to other reports, the presence of *Pseudomonas*, *Proteus*,  
204 *Enterobacter cloacae* and gram-positive bacteria was infrequent (8,22).

205 While it is true that the types and frequencies of bacteria detected are similar to those reported in the  
206 literature, there are differences with respect to antimicrobial susceptibility patterns. Overall, our study  
207 detected a high prevalence of bacteria resistant to first-line antibiotics. Approximately 30% of the  
208 enterobacteria were resistant to 1st generation cephalosporins, quinolones and trimethoprim-  
209 sulfamethoxazole, whereas 20% were resistant to 2nd and 3rd generation cephalosporins. We observed



210 an opposite situation for piperacillin-tazobactam, carbapenems and amikacin, which presented overall  
211 resistance rates below 5%, making them good empirical therapeutic options. The same concept can be  
212 applicable to vancomycin when infection by gram-positive bacteria is suspected, given resistance rates of  
213 less than 11% (Table 4).

214 When analyzing the susceptibility patterns of each of the bacteria, we observed that the resistance rates  
215 of *Escherichia coli* strains to 1st generation cephalosporins, ciprofloxacin and trimethoprim-  
216 sulfamethoxazole exceeded 30%. For 2nd and 3rd generation cephalosporins, resistance rates were lower,  
217 but above the thresholds suggested by clinical guidelines for their empirical use as 1st line antibiotics. On  
218 the other hand, amikacin, carbapenems and piperacillin-tazobactam showed resistance rates below 1%.  
219 Previous studies have reported mixed results. In Chile, the latest report from the Bacterial Resistance  
220 Collaborative Group (2012) reported lower resistance of *Escherichia coli* to ciprofloxacin and ceftriaxone  
221 (22.8% and 7.8%, respectively) in adult ambulatory urine cultures, but similar rates among 1st generation  
222 cephalosporins, nitrofurantoin and amikacin (37.6%, 4.7% and 0.1%). Although these data are not  
223 completely adaptable to the type of patients included in this study, our results show a clear increase in  
224 the rate of bacterial resistance for 3rd generation cephalosporins (23) .

225 Studies that included patients similar to ours (hospitalized) have shown disparate results. Jia et al. (24)  
226 reported higher resistance rates in Asian patients for ciprofloxacin (50.2%), trimethoprim-  
227 sulfamethoxazole (55.6%), as well as 2nd and 3rd generation cephalosporins (38%). However, there was  
228 a similarity regarding resistance for amikacin, nitrofurantoin and carbapenems. Mitcho et al. in Poland  
229 reported much lower resistance rates for *E. coli* for 3rd generation cephalosporins (13%), but higher for  
230 amikacin (11.8%) and piperacillin-tazobactam (23%) (22). Gajdács et al. also reported low resistance rates  
231 for 3rd generation cephalosporins (13.1%) in older Hungarian adults, and were similar to our findings for  
232 the rest of the antibiotics. It should be noted that, in this study, the authors did not define whether the  
233 UTIs were acquired before or during the hospital stay (25).

234 Regarding the second most prevalent bacterium (i.e., *Klebsiella spp*), its strains presented the highest  
235 resistance rates for all antibiotics, with only amikacin, imipenem and meropenem suggested as good  
236 empirical therapeutic options. Similar results were reported by Hrbacek et al. in hospitalized patients,  
237 differing only for piperacillin-tazobactam, where resistance was much lower (17%) (26). Gajdács et al.  
238 detected differences only for trimethoprim-sulfamethoxazole and 3rd generation cephalosporins, which  
239 had lower resistance rates than ours (27.8% and 27.7%, respectively) (25). It should be noted that in both  
240 studies it was not possible to discern whether the cultures corresponded to community-acquired or  
241 nosocomial infections.

242 Although infections by gram-positive bacteria were observed at low frequencies, *Enterococcus spp.*  
243 ranked third with a rate of 8.6% (6.7% for *E. faecalis* and 1.9% for *E. faecium*). Resistance to ampicillin was  
244 null for *E. faecalis*, but very high for *E. faecium*. Something similar occurred for nitrofurantoin (0% and  
245 68%) and vancomycin (0% and 56.3%). It is noteworthy that resistance to quinolones was high for both  
246 *Enterococcus*, being higher for *E. faecium*. The resistance patterns detected by Hrbacek et al. and Gajdács  
247 et al. were similar. However, their data combined both types of *Enterococcus* (25,26).

248 Our study has some limitations. Few patients belonging to the public health care center were included,  
249 which could affect the extrapolation of the results to the entire population. On the other hand, the  
250 susceptibility of some currently available antibiotics, such as Fosfomycin and new cephalosporins  
251 associated with beta-lactamase inhibitors, was not studied.

252 Among the main strengths of our study is the presence of a spectrum of patients of high frequency and  
253 clinical relevance, who have been underrepresented in published studies, including patients requiring  
254 hospitalization for a community-acquired infection. Also noteworthy is the prospective nature and the  
255 recruitment of a large number of patients.

256 Our data show that resistance rates for the most frequently-used antibiotics in our country are well above  
257 the recommended threshold for the selection of empirically-founded antibiotics. It is suggested here that  
258 the use of quinolones (ciprofloxacin) and cephalosporins could be replaced by amikacin. This switch  
259 represents further benefits in relation to its low cost and easy administration. In view of the latter, we  
260 believe that the recommendations of the current guidelines should be reviewed and updated.

261 Finally, our results emphasize the importance of having local information on antimicrobial susceptibility,  
262 especially for patients who develop community infections with risk factors associated to hospital-acquired  
263 infections. These results can offer medical teams more knowledge and tools to select appropriate  
264 antibiotic treatments before obtaining urine cultures and antibiograms, thus improving morbimortality  
265 and length of stay of patients with CA-UTI.

## 266 **ACKNOWLEDGMENTS**

267  
268 We thank Carolina Henriquez for her excellent logistic support during the execution of the study. Thanks  
269 to Camila Marti, Jose Maria Garcia, Miguel Cantillana, Jennifer Vilo and Mayerling Malig for their support  
270 in patient recruitment, as well as to Dr. Patricia García for her technical assistance from the clinical  
271 laboratory service

## REFERENCES

1. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. *Lancet*. 2020;395(10219):200–11.
2. Nicolle LE. Urinary Tract Infections in the Older Adult. *Clin Geriatr Med*. 2016;32(3):523–38.
3. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. *Infect Dis Clin North Am*. 1997 Sep;11(3):551–81.
4. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis*. 2011 Mar 1;52(5):e103-20.
5. Liu VX, Fielding-Singh V, Greene JD, Baker JM, Iwashyna TJ, Bhattacharya J, et al. The Timing of Early Antibiotics and Hospital Mortality in Sepsis. *Am J Respir Crit Care Med*. 2017;196(7):856–63.
6. Sterling SA, Miller WR, Pryor J, Puskarich MA, Jones AE. The Impact of Timing of Antibiotics on Outcomes in Severe Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. *Crit Care Med*. 2015 Sep;43(9):1907–15.
7. Aguilar-Duran S, Horcajada JP, Sorlí L, Montero M, Salvadó M, Grau S, et al. Community-onset healthcare-related urinary tract infections: comparison with community and hospital-acquired urinary tract infections. *J Infect*. 2012 May;64(5):478–83.
8. Horcajada JP, Shaw E, Padilla B, Pintado V, Calbo E, Benito N, et al. Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. *Clin Microbiol Infect*. 2013 Oct;19(10):962–8.
9. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of *Escherichia coli* from community-acquired urinary tract infections in Europe: the ECO-SENS study revisited. *Int J Antimicrob Agents*. 2012 Jan;39(1):45–51.
10. Arslan H, Azap OK, Ergönül O, Timurkaynak F, Urinary Tract Infection Study Group. Risk factors for ciprofloxacin resistance among *Escherichia coli* strains isolated from community-acquired urinary tract infections in Turkey. *J Antimicrob Chemother*. 2005 Nov;56(5):914–8.
11. Lee DS, Lee CB, Lee SJ. Prevalence and risk factors for extended spectrum Beta-lactamase-producing uropathogens in patients with urinary tract infection. *Korean J Urol*. 2010 Jul;51(7):492–7.
12. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. *Chest*. 2000 Jul;118(1):146–55.

13. Lee SS, Kim Y, Chung DR. Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis. *J Infect*. 2011 Feb; 62(2): 159–64.
14. Lau SM, Peng MY, Chang FY. Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and non-bacteremic community-acquired urinary tract infection. *J Microbiol Immunol Infect*. 2004 Jun; 37(3): 185–91.
15. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. *Chest*. 2009 Nov; 136(5): 1237–48.
16. Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2019; 68(10): e83–110.
17. Rowe TA, Juthani-Mehta M. Diagnosis and management of urinary tract infection in older adults. *Infect Dis Clin North Am*. 2014 Mar; 28(1): 75–89.
18. M-100 Performance Standards for Antimicrobial Susceptibility Testing. 32nd ed. Wayne, PA.: Clinical and Laboratory Standards Institute; 2022.
19. Simmering JE, Tang F, Cavanaugh JE, Polgreen LA, Polgreen PM. The Increase in Hospitalizations for Urinary Tract Infections and the Associated Costs in the United States, 1998-2011. *Open Forum Infect Dis*. 2017; 4(1):ofw281.
20. Goldstein E, MacFadden DR, Karaca Z, Steiner CA, Viboud C, Lipsitch M. Antimicrobial resistance prevalence, rates of hospitalization with septicemia and rates of mortality with sepsis in adults in different US states. *Int J Antimicrob Agents*. 2019 Jul; 54(1): 23–34.
21. Ministerio de Salud . Gobierno de Chile. Departamento de Estadísticas e Información de Salud. <https://deis.minsal.cl/>. 2022.
22. MICHNO M, SYDOR A, WAŁASZEK M, SUŁOWICZ W. Microbiology and Drug Resistance of Pathogens in Patients Hospitalized at the Nephrology Department in the South of Poland. *Pol J Microbiol*. 2018 Jan 1; 67(4): 517–24.
23. Cifuentes-D M, Silva F, García P, Bello H, Briceño I, Calvo-A M, et al. [Antimicrobial susceptibility in Chile 2012]. *Rev Chilena Infectol*. 2014 Apr; 31(2): 123–30.
24. Jia P, Zhu Y, Li X, Kudinha T, Yang Y, Zhang G, et al. High Prevalence of Extended-Spectrum Beta-Lactamases in *Escherichia coli* Strains Collected From Strictly Defined Community-Acquired Urinary Tract Infections in Adults in China: A Multicenter Prospective Clinical Microbiological and Molecular Study. *Front Microbiol*. 2021; 12: 663033.
25. Gajdács M, Ábrók M, Lázár A, Burián K. Urinary Tract Infections in Elderly Patients: A 10-Year Study on Their Epidemiology and Antibiotic Resistance Based on the WHO Access, Watch, Reserve (AWaRe) Classification. *Antibiotics (Basel)*. 2021 Sep 11; 10 (9).

26. Hrbacek J, Cermak P, Zachoval R. Current antibiotic resistance patterns of rare uropathogens: survey from Central European Urology Department 2011-2019. BMC Urol. 2021 Apr 13; 21(1): 61.

	n = 830
Age (years), median (range)	66.5 (18-102)
Female sex. % (n)	64.1% (532)
<b>Comorbidities % (n)</b>	
Diabetes mellitus	33.9% (281)
Chronic renal insufficiency	21.4% (178)
Cardiac insufficiency	11.3% (94)
Cerebrovascular accident	7.2% (60)
Dementia	14.0% (116)
Active solid or hematologic neoplasm	17.0% (141)
Solid organ or bone marrow transplant	4.7% (39)
<b>Hospitalizations in the last 12 months % (n)</b>	
1 hospitalization	25.9% (215)
2 hospitalizations	10.0% (83)
3 hospitalizations	4.7% (39)
4 hospitalizations	1.2% (10)
5 hospitalizations	1.4% (12)
Use of permanent urinary catheter, % (n)	13.3% (110)
Anatomical or functional alterations of the urinary tract, % (n)	28.3% (235)
Instrumentalization of the urinary tract in the last 12 months, % (n)	14.1% (117)
Previous cultures for resistant bacteria in the last 12 months, % (n)	24.5% (203)
Antibiotic use in the last 90 days, % (n)	45.7% (379)
<b>Income unit % (n)</b>	
Low complexity	60.5% (502)
Medium complexity	35.5% (295)

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.27.22283981>; this version posted December 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

High complexity	4.0% (33)
Length of stay, median (range)	10.5 (1-121)

**Table 1.** Clinical and demographic characteristics of the patients participating in the study.

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.27.22283981>; this version posted December 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

	Both centers (n=830)	HCUC (n=736)	HSR (n=94)	p
Bacterial isolate	% (n)	% (n)	% (n)	
<i>Escherichia coli</i>	68.1% (565)	69.0% (508)	60.6% (57)	p >0.05
<i>Klebsiella spp.</i>	17.7% (147)	16.6% (122)	26.6% (25)	<b>p 0.02</b>
<i>Enterococcus faecalis</i>	6.7% (56)	7.2% (53)	3.2% (3)	p >0.05
<i>Proteus spp.</i>	4.6% (38)	5.0% (37)	1.1% (1)	p >0.05
<i>Pseudomonas aeruginosa</i>	2.5% (21)	4.8% (19)	2.1% (2)	p >0.05
<i>Enterococcus faecium</i>	1.9% (16)	1.8% (13)	3.2% (3)	p >0.05
<i>Staphylococcus spp.</i>	1.9% (16)	1.8% (13)	3.2% (3)	p >0.05
<i>Enterobacter cloacae (complex)</i>	1.1% (9)	1.1% (8)	1.1% (1)	p >0.05
Other Enterobacteriaceae*	1.1% (9)	1.2% (9)	0.0% (0)	p >0.05
Other bacteria**	0.7% (6)	0.8% (6)	0.0% (0)	p >0.05

**Table 2.** Type of bacteria isolated in urine cultures, showing differences according to care center.

\* The following are grouped under "Other Enterobacteriaceae": *Morganella morganii* (n: 4), *Citrobacter spp.* (n: 3), *Serratia marcescens* (n: 2).

\*\* The following are grouped under "Other Bacteria": *Streptococcus agalactiae group B* (n: 2), *Streptococcus gallolyticus/equinus complex* (n: 1), *Enterococcus gallinarum* (n: 1), *Enterococcus avium* (n: 1) and *Achromobacter spp.* (n: 1).



	Men (n:298)	Women (n:532)	p value	≥65 years (n:498)	<65 years (n:332)	p value
Bacterial isolate	% (n)	% (n)		% (n)	% (n)	
<i>Escherichia coli</i>	51.7% (154)	77.3% (411)	<0.01	66.3% (330)	70.8% (235)	0.17
<i>Klebsiella spp.</i>	24.2% (72)	14.1% (75)	<0.01	16.9% (84)	19.0% (63)	0.47
<i>Enterococcus faecalis</i>	10.1% (30)	4.9% (26)	<0.01	8.2% (41)	4.5% (15)	0.03
<i>Proteus spp.</i>	7 % (21)	3.2% (17)	0.01	5.2% (26)	3.6% (12)	0.27
<i>Pseudomonas aeruginosa</i>	4.7% (14)	1.3% (7)	<0.01	3.6% (18)	0.9% (3)	0.01
<i>Enterococcus faecium</i>	1.7% (5)	2.1% (11)	0.69	1.6% (8)	2.4% (8)	0.4
<i>Staphylococcus spp.</i>	3.7% (11)	0.9% (5)	0.01	2 % (10)	1.8% (6)	0.83
<i>Enterobacter cloacae</i> (complex)	2% (6)	0.8% (4)	0.1	1 % (5)	1.5% (5)	0.71
Other Enterobacteriaceae*	1.7% (5)	0.8% (4)	0.18	1.2% (6)	0.9% (3)	0.44
Other bacteria**	1.3% (4)	0.4% (2)	0.6	1 % (5)	0,3% (1)	0.72

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.27.22283941>; this version posted December 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**Table 3.** Type of bacteria isolated in urine cultures, showing differences by sex and age group in both recruiting centers

Antibiotic	<i>Escherichia coli</i> (n: 565); % (n)	<i>Klebsiella spp.</i> (n:147); % (n)	<i>Proteus spp.</i> (n:38); % (n)	<i>Enterobacter cloacae</i> (n:9); % (n)	<i>Pseudomona aeruginosa</i> (n:21); % (n)	<i>Enterococcus faecalis</i> (n:56); % (n)	<i>Enterococcus faecium</i> (n:16); % (n)	<i>Staphylococcus spp.</i> (n:16); % (n)	Total; % (n)
Cephalosporins 1 <sup>st</sup>	31.9% (180)	53.1% (78)	15.8% (6)	N/A	N/A	N/A	N/A	N/A	35.2% (264)
Cephalosporins 2 <sup>nd</sup>	15.0% (85)	39.5% (58)	13.1% (5)	N/A	N/A	N/A	N/A	N/A	19.7% (148)
Nitrofurantoin	3.9% (22)	32.7% (48)	36.8% (33)	44.4% (4)	N/A	0.0% (0)	68.8% (11)	0.0% (0)	13.9% (118)
Ciprofloxacin	35.2% (199)	44.2% (65)	18.4% (7)	33.3% (3)	28.6% (6)	37.5% (21)	81.3% (13)	N/A	36.9% (314)
Gentamicin	11.3% (64)	32.7% (48)	5.3% (2)	22.2% (2)	19.0% (4)	N/A	N/A	12.5% (2)	15.3% (122)
Amikacin	0.2% (1)	6.8% (10)	2.6% (1)	22.2% (2)	0.0% (0)	N/A	N/A	N/A	1.8% (14)
Trimethoprim-Sulfamethoxazole	32.7% (185)	44.2% (65)	21.1% (8)	44.4% (4)	N/A	N/A	N/A	12.5% (2)	34.1% (264)
Cephalosporins 3 <sup>rd</sup>	20.5% (116)	53.1% (78)	18.4% (7)	44.4% (4)	33.3% (7)	N/A	N/A	N/A	27.2% (212)
Cefoperazone-Sulbactam	N/A	N/A	N/A	N/A	0.0% (0)	N/A	N/A	N/A	0.0% (0)
Piperacillin-tazobactam	0.7% (4)	17.7% (26)	2.6% (1)	44.4% (4)	4.8% (1)	N/A	N/A	N/A	4.6% (36)
Ertapenem	0.6% (3)	17.7% (26)	0.0% (0)	33.3% (3)	N/A	N/A	N/A	N/A	4.2% (32)
Imipenem	0.2% (1)	3.4% (5)	0.0% (0)	11.1% (1)	33.3% (7)	N/A	N/A	N/A	1.8% (14)
Meropenem	0.0% (0)	4.1% (6)	0.0% (0)	0.0% (0)	14.3% (3)	N/A	N/A	N/A	1.2% (9)
Ampicillin	N/A	N/A	N/A	N/A	N/A	0.0% (0)	81.3% (13)	N/A	18% (13)

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.27.22283981>; this version posted December 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Oxacillin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	25.0% (4)	25.0% (4)
Vancomycin	N/A	N/A	N/A	N/A	N/A	0.0% (0)	56.3% (9)	0.0% (0)	10.2% (9)
Teicoplanin	N/A	N/A	N/A	N/A	N/A	0.0% (0)	6.3% (1)	N/A	1.4% (1)
Linezolid	N/A	N/A	N/A	N/A	N/A	0.0% (0)	0.0% (0)	N/A	0.0% (0)

**Table 4. Antibiotic resistance pattern for total bacteria found in urine cultures of patients with community-acquired urinary tract infection admitted to HCUC or HSR. N/A: not applicable.**

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.27.22283981>; this version posted December 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Antibiotic	<i>Escherichia Coli</i>			<i>Klebsiella spp</i>		
	HCUC (n:508); % (n)	HSR (n:57); % (n)	<i>p</i>	HCUC (n:122); % (n)	HSR (n:25); % (n)	<i>p</i>
Cephalosporins 1 <sup>st</sup>	30.3% (154)	45.6% (26)	0.018	50.8% (62)	64.0% (16)	0.01
Cephalosporins 2 <sup>nd</sup>	15.0% (85)	N/A	-	47.5% (58)	N/A	-
Nitrofurantoin	3.3% (17)	8.8% (5)	0.04	29.5% (36)	48.0% (12)	0.22
Ciprofloxacin	34.3% (174)	43.9% (25)	0.14	41.0% (50)	60.0% (15)	0.07
Gentamicin	12.0% (61)	5.3% (3)	0.12	31.1% (38)	40.0% (10)	0.08
Amikacin	0.2% (1)	0.0% (0)	0.18	6.6% (8)	8.0% (2)	0.86
Trimethoprim-sulfamethoxazole	31.9% (162)	40.4% (23)	0.19	43.4% (53)	48.0% (12)	0.38
Cephalosporins 3 <sup>rd</sup>	20.3% (103)	22.8% (13)	0.65	53.3% (65)	52.0% (13)	0.9
Piperacillin-Tazobactam	0.8% (4)	7.0% (4)	<0.01	12.3% (15)	44.0% (11)	<0.01
Ertapenem	0.4% (2)	1.8% (1)	0.7	13.9% (17)	36.0% (9)	<0.01
Imipenem	0.2% (1)	0.0% (0)	0.18	2.5% (3)	8.0% (2)	0.43
Meropenem	0.0% (0)	0.0% (0)	-	3.3% (4)	8.0% (2)	0.86

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.27.2283981>; this version posted December 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**Table 5.** Antimicrobial resistance profile for *E. coli* and *Klebsiella spp.* in each hospital center, antibiograms reported from urine cultures.

Antibiotic	Men; % (n)	Women; % (n)	p	≥65 years % (n)	<65 years % (n)	p
Cephalosporins 1 <sup>st</sup>	49.0% (121)	28.4% (143)	<0.01	32.7% (144)	38.7% (120)	0.09
Cephalosporins 2 <sup>nd</sup>	31.2% (77)	14.1% (71)	<0.01	21.1% (93)	17.7% (55)	0.22
Nitrofurantoin	19.7% (59)	10.8% (59)	<0.01	13.5% (68)	14.6% (50)	
Ciprofloxacin	51.0% (154)	29.1% (160)	<0.01	35.9% (184)	38.2% (130)	
Gentamicin	21.2% (59)	12.2% (63)	<0.01	15.4% (73)	15.2% (49)	
Trimethoprim- Sulfamethoxazole	38.3% (101)	31.9% (163)	0.05	33.6% (153)	34.7% (111)	
Cephalosporins 3 <sup>rd</sup>	42.7% (114)	19.1% (98)	<0.01	28.1% (130)	25.9% (82)	0.32
Piperacillin-Tazobactam	8.6% (23)	2.5% (13)	<0.01	4.5% (21)	4.7% (15)	0.92
Ertapenem	9.1% (23)	1.8% (9)	<0.01	3.6% (16)	5.1% (16)	0.31
Imipenem	3.4% (9)	1.0% (5)	0.01	2.2% (10)	1.3% (4)	0.32
Meropenem	3.0% (8)	0.2% (1)	<0.01	1.3% (6)	0.9% (3)	0.61
Amikacin	4.9% (13)	0.2% (1)	<0.01	1.5% (7)	2.2% (7)	0.51
Oxacillin	36.4% (4)	0.0% (0)	0.45	30.0% (3)	16.7% (1)	
Vancomycin	4.3% (2)	16.7% (7)	0.12	8.5% (5)	13.8% (4)	
Teicoplanin	0.0% (0)	2.7% (1)	-	2.0% (1)	0.0% (0)	
Linezolid	0.0% (0)	0.0% (0)	-	0.0% (0)	0.0% (0)	

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.27.22283981>; this version posted December 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**Table 6.** Overall antibiotic resistance patterns for bacteria found in urine cultures of patients with community-acquired urinary tract infection admitted to HCUC or HSR, showing differences by sex and age group. It should be noted that bacteria classified as \*other enterobacteria and \*\*other bacteria were not considered for the calculation of % resistance. The following were considered: *Escherichia coli*, *Klebsiella spp*, *Enterococcus faecalis*, *Enterococcus faecium*, *Proteus spp*, *Pseudomonas aeruginosa*, *Enterobacter cloacae*, *Staphylococcus spp*.